19 MayAbout RVX 208RVX 208.

About RVX – 208RVX – 208, a novel low molecular weight agents endogenous endogenous ApoA-I production, is positioned, thereby preventing the most promising agents for the treatment of emerging atherosclerosis. To the Company’s knowledge RVX-208 is the only novel small molecule that is specifically designed to increase ApoA-I production and thereby raise HDL levels thus enhancing HDL functionality to expand reverse cholesterol transport . RCT is a way is transported to the accumulated cholesterol from the arterial wall to the liver for excretion, thereby preventing atherosclerosis.

After Katherine Swartz, an economist at Harvard School of Public Health, many countries is examining ways of health insurance for small companies through high-risk pools, individuals with pre – to reduce the subsidized insurance offer for individuals with pre – existing or chronic conditions Tahmincioglu, New York Times.. Increase of 7 percent Of Health Insurance Hinders start-upshealth insurance costs increasing chatter start-up companies and in some cases would-be entrepreneurs on the edge, especially those with pre-existing conditions, Keep The New York Times reports.In products which to be recycled and damaged, was cause to convert without special equipment.. With support to the research out the Department of Energy, Sloan Foundation and research Corporation, identified Ozerov new reacting catalytic method for a class of carborane silylium compounds, the ties causes of representative HCFC at room temperature share, Your carbon-fluorine linkages of carbon-hydrogen bonds. The silylium catalyst leads the critical task of the destruction of F bond by abstraction of fluoride of the fluorinated hydrocarbon and attachment to a the silicon atom the final product connect to a silicon-fluorine bond, that is no longer a green house threat.

Conversion of HFCs remains a challenge, and our research effort aimed at designing even longer active catalyst able PFC activate, said Ozerov.